“…Second-generation Aβ vaccines that have subsequently been tested in clinical trials (Table 1) include CAD106, ACC-001 (vanutide cridificar), Lu AF20513, UB-311, ACI-24, V-950, ABvac40, AD01, AD02, and AD03 [3][4][5]14,61,62]. CAD106 [1,[3][4][5]14,[61][62][63][64] is based on the first 6 amino acids of Aβ, ACC-001 [1,3,5,14,61,62,65] is based on the first 7 amino acids, Lu AF20513 [3][4][5]61,62] is based on the first 12 amino acids, UB-311 [3][4][5]14,61,62,66] is based on the first 14 amino acids, and ACI-24 [1,3,5,14,61,62] is based on the first 15 amino acids, whereas V-950 also employs an N-terminal Aβ peptide fragment [3,61,62], reported to be Aβ(1-15) [66]. On the other hand, it should be noticed that ABvac40 vaccine [1,…”